Michael H. Davidson to Clinical Trials, Phase I as Topic
This is a "connection" page, showing publications Michael H. Davidson has written about Clinical Trials, Phase I as Topic.
Connection Strength
0.106
-
Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. J Clin Lipidol. 2013 May-Jun; 7(3 Suppl):S11-5.
Score: 0.106